- Home
- Products
Blenrep (Belantamab Mafodotin-blmf)
Blenrep (Belantamab Mafodotin-blmf)
- Medicine Name: Blenrep
- Generic Name: Belantamab Mafodotin-blmf
- Dosage Form & Strength: 100 mg lyophilized powder for injection in a single-dose vial
- Manufactured By: GlaxoSmithKline
Blenrep is a BCMA-directed antibody-drug conjugate used for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies, including:
- A proteasome inhibitor
- An anti-CD38 monoclonal antibody
- An immunomodulatory agent
Recommended Dosage:
2.5 mg/kg of actual body weight, administered as an intravenous infusion over approximately 30 minutes once every 3 weeks, continued until disease progression or unacceptable toxicity.
Conduct baseline ophthalmic exams (visual acuity, slit lamp) before starting and prior to each dose. Follow-up exams should occur 1 week after dosing and within 2 weeks prior to the next dose.
Use preservative-free lubricating eye drops at least four times daily from the start of treatment. Avoid contact lenses unless advised by an ophthalmologist.
Withhold treatment if eye-related symptoms worsen. Resume only after improvement, and adjust dose based on severity.
Monitor patients for infusion-related reactions. In cases of Grade 2 or 3 reactions, pause infusion, provide supportive care, and resume at a slower rate after recovery.
Blenrep may cause fetal harm due to its cytotoxic action. Women should use effective contraception during treatment and for 3 months after the last dose.
Breastfeeding is not recommended during and for 3 months after treatment.
Advise patients to exercise caution while driving or using machinery due to the risk of blurred vision or visual impairment.
To import Blenrep (Belantamab Mafodotin-blmf) via GlobalRareMeds, the following documents are required:
- Valid prescription from a qualified oncologist
- Patient’s diagnostic reports confirming the indication
- Government-issued ID of the patient
Order Confirmation:
Orders are confirmed only after receipt and verification of the above documents. An import permit may be required based on local regulatory requirements.
GlobalRareMeds sources Blenrep 100 mg from authorized pharmaceutical distributors in the USA, Canada, Europe, and Australia.
Dispatches are managed via our fulfillment center in Ambernath, Thane District, with strict adherence to cold chain logistics and pharmacist validation.
Delivery coverage includes:
- India – All major cities including Mumbai, Delhi, Bangalore, Chennai, Hyderabad, Kolkata, Ahmedabad, Pune, and others
- International locations, subject to legal compliance
📧 Email: info@globalraremeds.com
📞 Call/WhatsApp: +91-99675 15602
Q. What is the generic name for Blenrep?
A. The generic name is Belantamab Mafodotin-blmf.
Q. Who manufactures Blenrep?
A. Blenrep is manufactured by GlaxoSmithKline.
Q. Is Blenrep FDA approved?
A. Yes, Blenrep received FDA approval on August 5, 2020.
Q. What is Blenrep used for?
A. Blenrep is indicated for adults with relapsed or refractory multiple myeloma who have undergone at least four prior lines of therapy.
Q. What form and strength is Blenrep available in?
A. Blenrep is available as a 100 mg lyophilized powder for injection in a single-dose vial.
Q. What are common side effects of Blenrep?
A. Side effects may include keratopathy, blurred vision, nausea, fatigue, fever, infusion-related reactions, and decreased visual acuity.
Q. How should Blenrep be stored?
A. Store refrigerated at 2°C to 8°C (36°F to 46°F). Handle as a hazardous agent with proper disposal measures.
Q. Can Blenrep be used during pregnancy or breastfeeding?
A. No. Blenrep may cause harm to the fetus. Effective contraception is required, and breastfeeding must be avoided for at least 3 months after the final dose.
Q. How can I buy Blenrep in India?
A. You can request access to Blenrep through GlobalRareMeds by submitting a valid prescription and required documentation. We ensure secure and regulatory-compliant delivery.
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
